Search clinical trials for: IMC-F106C

Total 1767 results

Immunocore Ltd

Recruiting

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Select Advanced Solid Tumors

United States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

United States, Australia
Scott & White Health Plan

Completed

Retrospective Data Analysis of VitalCare Targeted Population Management on Scott and White Chronically Ill Beneficiaries

Chronic Illness

United States
Eli Lilly and Company

Completed

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

Malignant Melanoma

United States
University of Valencia

Completed

Preventive Physiotherapy Intervention in Elderly People With Sarcopenia

Sarcopenia | Syndrome; Institutionalization

Spain
Hoffmann-La Roche

Completed

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell

United Kingdom, Czechia, Germany, Poland, Spain, Switzerland
ImmuneOncia Therapeutics Inc.

Not yet recruiting

A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)

TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
Innovative Med Concepts, LLC

Completed

A Study of IMC-1 In Patients With Fibromyalgia

Chronic Pain | Fibromyalgia | Myofascial Pain

United States
ImmuneOncia Therapeutics Inc.

Recruiting

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

Advanced Cancer

Korea, Republic of
ImmuneOncia Therapeutics Inc.

Completed

A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Lymphoma | Solid Tumor

Korea, Republic of, United States
Eli Lilly and Company

Completed

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Neoplasms | Neoplasm Metastasis

United States
Chang Gung Memorial Hospital

Completed

Inspiratory Muscle Training in Stroke Patients With Stable Congestive Heart Failure: a Prospective RCT.

Dyspnea

Taiwan
Dokuz Eylul University

Completed

The Effect of Inspiratory Muscle Warm-Up in Patients With COPD

Chronic Obstructive Pulmonary Disease | COPD

Turkey
CorAssist Cadiovascular Ltd.

Terminated

ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study (ImCardia)

Heart Failure With Normal Ejection Fraction
Virios Therapeutics, Inc.

Completed

Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1 (FORTRESS)

Fibromyalgia

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
ImmuneOncia Therapeutics Inc.

Active, not recruiting

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Extranodal NK/T-cell Lymphoma, Nasal Type | Extranodal NK/T-cell Lymphoma

Korea, Republic of
ImmuneOncia Therapeutics Inc.

Completed

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Solid Tumor | Metastasis | Locally Advanced

Korea, Republic of
Eli Lilly and Company

Completed

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

Advanced Solid Tumors

United States
Eli Lilly and Company

Completed

A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Neoplasms

United States
Eli Lilly and Company

Completed

A Study of IMC-TR1 in Participants With Advanced Solid Tumors

Neoplasms | Tumor

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Rectal Cancer | Colon Cancer

United States, Canada
Eli Lilly and Company

Completed

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Neoplasms

United States
Eli Lilly and Company

Terminated

Study of IMC-EB10 in Participant With Leukemia

Myeloid Leukemia

United States
Emory University
University of Calgary; Children's Hospital Medical Center, Cincinnati; Heidelberg... and other collaborators

Recruiting

Endovascular Therapy for Low NIHSS Ischemic Strokes (ENDOLOW)

Cerebral Ischemia

United States, Canada, Germany
Sorrento Therapeutics, Inc.

Withdrawn

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Diffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
National Cancer Institute (NCI)

Completed

Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy

Thymic Carcinoma | Thymoma | Thymic Carcinoid | Thymic Neuroendocrine Tumors

United States
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Hepatocellular Carcinoma

United States
Asan Medical Center

Recruiting

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers (NeoChance)

Subjects With Resectable and Localized Gastric Cancer | Subjects With Resectable Esophageal Cancer or Liver Cancer | Subjects With Resectable Liver Cancer

Korea, Republic of
National Cancer Institute (NCI)

Completed

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

Peritoneal Mesothelioma | Pleural Mesothelioma

United States
University of Valencia

Completed

Respiratory Muscle Training in Institutionalized Elderly Population

Muscle Weakness | Other Diagnoses, Comorbidities, and Complications | Syndrome; Institutionalization

Spain
M.D. Anderson Cancer Center
Eli Lilly and Company

Completed

Preoperative Treatment With Cetuximab and/or IMC-A12

Head and Neck Squamous Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

Melanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic Melanoma

United States
Eli Lilly and Company

Completed

Study of Ramucirumab in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States, United Kingdom
Eli Lilly and Company
Parexel; Medidata Solutions

Completed

A Study of IMC-A12 in Advanced Solid Tumors

Tumors

Japan
Eli Lilly and Company

Completed

A Study of IMC-RON8 in Advanced Solid Tumors

Cancer

United States
Eli Lilly and Company

Completed

Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available

Solid Tumors

United States
Eli Lilly and Company

Completed

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Breast Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma

United States
Eli Lilly and Company

Terminated

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor (GIST)

United States, Belgium, Germany, Netherlands, Poland, Spain
National Cancer Institute (NCI)

Completed

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Wilms Tumor and Other Childhood Kidney Tumors | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Neuroectodermal Tumor and other conditions

United States, Canada, Australia
Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Gilead Sciences

Terminated

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF (ARTEMIS-IPF)

Idiopathic Pulmonary Fibrosis

Belgium, France, Germany, Israel, Spain, United States, Switzerland, Colombia, Mexico, Italy, Czech Republic, Australia, Canada, Austria, Poland, United Kingdom, Argentina, Netherlands, Peru, Ireland, Brazil, Chile
Eli Lilly and Company

Completed

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Breast Cancer

United States, Canada, Australia, Belgium, Brazil, Croatia, Czechia, Egypt, Germany, Ireland, Israel, Korea, Republic of, Lebanon, New Zealand, Peru, Poland, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, United...
Eli Lilly and Company

Completed

Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy

Solid Tumors

Netherlands
Eli Lilly and Company

Completed

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Poland, Romania, Hungary, Russian Federation, Australia, France, Argentina, United Kingdom, New Zealand, Turkey, Slovakia
Eli Lilly and Company

Completed

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Carcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal Pelvis

United States, Canada
Eli Lilly and Company

Completed

A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer

Gastric Cancer

Japan
Eli Lilly and Company
Parexel

Completed

Study of IMC-1121B in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Eli Lilly and Company

Completed

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Adenocarcinoma

Japan

Search clinical trials for: IMC-F106C

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations